RNA Supply Chain Resources

  1. mRNA Vaccine Development: Planning, Workflow, Supply Chain Success 5/17/2022

    A review of insights derived from the development of mRNA-based COVID-19 vaccines and how they can be applied to accelerate progress in the manufacture of vaccines and therapeutics moving forward.

  2. GMP-Source® And Phase-Appropriate Use For Early-Stage Clinical Trials 9/16/2021

    GMP-Source is a more robust, less rigid alternative to full cGMP production that mirrors nearly all of the oversight and quality standards of full cGMP production while relaxing certain commercial standards, helping companies overcome the hurdles that can stall early development.

  3. A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy 4/14/2022

    We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.

  4. Pioneering The Future Of Pharmaceutical Supply Chains

    Drive the efficiency and resiliency of supply chains by integrating automation, AI, and effective communication, ensuring the successful distribution of lifesaving medicinal products.

  5. Delivering Global Media Manufacturing Consistency Through Site-To-Site Equivalency 7/8/2024

    Explore a program focused on achieving process consistency through risk mitigation in four key areas: raw materials sourcing, equipment, manufacturing processes, and finished product testing.

  6. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

    We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.

  7. Expectations On The Pathway To GMP For Gene-Modified Cell Therapies 6/21/2023

    Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.

  8. Optimization Of Transient Transfection Of MSCs With Plasmid DNA Or mRNA 11/1/2022

    Read through the results of our efforts to produce an optimal protocol for the transient transfection of hMSCs with pDNA or mRNA using non-viral means.

  9. Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs 8/14/2023

    Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.

  10. Advancing mRNA Therapeutics With High Performance RNA Polymerases 2/9/2026

    Learn how optimized RNA polymerases enhance mRNA therapeutic quality and transcript integrity by increasing yield and capping efficiency while reducing double-stranded RNA impurities.